These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 18785683

  • 1. Use of proliferation tests to evaluate the effects of complexing agents on beryllium toxicity.
    Stephan CH, Sauvé S, Fournier M, Brousseau P.
    J Appl Toxicol; 2009 Jan; 29(1):27-35. PubMed ID: 18785683
    [Abstract] [Full Text] [Related]

  • 2. Protective effect of Tiron (4,5-dihydroxybenzene-1,3-disulfonic acid disodium salt) against beryllium-induced maternal and fetal toxicity in rats.
    Sharma P, Shah A, Shukla S.
    Arch Toxicol; 2002 Aug; 76(8):442-8. PubMed ID: 12185411
    [Abstract] [Full Text] [Related]

  • 3. Partial IL-10 inhibition of the cell-mediated immune response in chronic beryllium disease.
    Tinkle SS, Kittle LA, Newman LS.
    J Immunol; 1999 Sep 01; 163(5):2747-53. PubMed ID: 10453017
    [Abstract] [Full Text] [Related]

  • 4. Comparative effectiveness of CaNa3DTPA and tiron along with alpha-tocopherol against beryllium-induced biochemical alterations in rats.
    Mathur R, Nirala SK, Mathur A.
    Indian J Exp Biol; 2004 Jun 01; 42(6):570-4. PubMed ID: 15260107
    [Abstract] [Full Text] [Related]

  • 5. Reversal of effects of intra peritoneally administered beryllium nitrate by tiron and CaNa3DTPA alone or in combination with alpha-tocopherol.
    Nirala SK, Bhadauria M, Upadhyay AK, Mathur R, Mathur A.
    Indian J Exp Biol; 2009 Dec 01; 47(12):955-63. PubMed ID: 20329698
    [Abstract] [Full Text] [Related]

  • 6. Comparative effectiveness of Tiron (4,5-dihydroxy benzene 1,3-disulphonic acid disodium salt) and CaNa2EDTA with time after beryllium poisoning.
    Sharma P, Shukla S.
    Indian J Exp Biol; 2000 Aug 01; 38(8):785-90. PubMed ID: 12557911
    [Abstract] [Full Text] [Related]

  • 7. Immunological responses in C3H/HeJ mice following nose-only inhalation exposure to different sizes of beryllium metal particles.
    Salehi F, Zayed J, Audusseau S, Muller C, Truchon G, Plamondon P, L'espérance G, Chevalier G, Mazer B.
    J Appl Toxicol; 2009 Jan 01; 29(1):61-8. PubMed ID: 18980269
    [Abstract] [Full Text] [Related]

  • 8. Process-related risk of beryllium sensitization and disease in a copper-beryllium alloy facility.
    Schuler CR, Kent MS, Deubner DC, Berakis MT, McCawley M, Henneberger PK, Rossman MD, Kreiss K.
    Am J Ind Med; 2005 Mar 01; 47(3):195-205. PubMed ID: 15712254
    [Abstract] [Full Text] [Related]

  • 9. Beryllium health effects in the era of the beryllium lymphocyte proliferation test.
    Maier LA.
    Appl Occup Environ Hyg; 2001 May 01; 16(5):514-20. PubMed ID: 11370931
    [Abstract] [Full Text] [Related]

  • 10. Beryllium-induced toxicity and its prevention by treatment with chelating agents.
    Sharma P, Johri S, Shukla S.
    J Appl Toxicol; 2000 May 01; 20(4):313-8. PubMed ID: 10942906
    [Abstract] [Full Text] [Related]

  • 11. Significance of the blood beryllium lymphocyte proliferation test.
    Newman LS.
    Environ Health Perspect; 1996 Oct 01; 104 Suppl 5(Suppl 5):953-6. PubMed ID: 8933041
    [Abstract] [Full Text] [Related]

  • 12. Immunology of chronic beryllium disease.
    Samuel G, Maier LA.
    Curr Opin Allergy Clin Immunol; 2008 Apr 01; 8(2):126-34. PubMed ID: 18317020
    [Abstract] [Full Text] [Related]

  • 13. Chronic beryllium disease: a hypersensitivity disorder.
    Rossman MD.
    Appl Occup Environ Hyg; 2001 May 01; 16(5):615-8. PubMed ID: 11370939
    [Abstract] [Full Text] [Related]

  • 14. Role of the berylliosis-associated HLA-DPGlu69 supratypic variant in determining the response to beryllium in a blood T-cells beryllium-stimulated proliferation test.
    Amicosante M, Deubner D, Saltini C.
    Sarcoidosis Vasc Diffuse Lung Dis; 2005 Oct 01; 22(3):175-9. PubMed ID: 16315779
    [Abstract] [Full Text] [Related]

  • 15. Beryllium hypersensitivity and chronic beryllium lung disease.
    Santo Tomas LH.
    Curr Opin Pulm Med; 2009 Mar 01; 15(2):165-9. PubMed ID: 19532033
    [Abstract] [Full Text] [Related]

  • 16. Immunogenetic factors in beryllium sensitization and chronic beryllium disease.
    Weston A, Snyder J, McCanlies EC, Schuler CR, Andrew ME, Kreiss K, Demchuk E.
    Mutat Res; 2005 Dec 30; 592(1-2):68-78. PubMed ID: 16054169
    [Abstract] [Full Text] [Related]

  • 17. The BeLPT: algorithms and implications.
    Middleton DC, Lewin MD, Kowalski PJ, Cox SS, Kleinbaum D.
    Am J Ind Med; 2006 Jan 30; 49(1):36-44. PubMed ID: 16362939
    [Abstract] [Full Text] [Related]

  • 18. The beryllium lymphocyte proliferation test: Relevant issues in beryllium health surveillance.
    Stange AW, Furman FJ, Hilmas DE.
    Am J Ind Med; 2004 Nov 30; 46(5):453-62. PubMed ID: 15490468
    [Abstract] [Full Text] [Related]

  • 19. Non-invasive diagnosis of chronic beryllium disease in workers exposed to hazardous dust in Israel.
    Fireman E, Mazor O, Kramer M, Priel I, Lerman Y.
    Occup Environ Med; 2010 Sep 30; 67(9):631-5. PubMed ID: 19955573
    [Abstract] [Full Text] [Related]

  • 20. Comparative analysis between CFSE flow cytometric and tritiated thymidine incorporation tests for beryllium sensitivity.
    Milovanova TN.
    Cytometry B Clin Cytom; 2007 Jul 30; 72(4):265-75. PubMed ID: 17328032
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.